infect
remain
lead
caus
mortal
morbid
first
month
hematopoiet
stem
cell
transplant
hsct
despit
advanc
prophylact
viral
fungal
therapi
minim
viral
fungal
burden
earli
hsct
breakthrough
viral
fungal
infect
remain
lifethreaten
viral
fungal
infect
effect
therapi
vaccin
strategi
induc
immun
cmv
began
limit
success
condit
regimen
hsct
vari
nonmyeloabl
myeloabl
creat
immunodefici
leav
allogen
hsct
recipi
suscept
viral
fungal
infect
immun
reconstitut
occur
first
month
hsct
immun
reconstitut
abrog
intens
immunosuppress
use
prevent
andor
control
gvhd
clearli
establish
kinet
rate
tcell
reconstitut
critic
control
viral
infect
factor
speed
tcell
recoveri
decreas
risk
viral
infect
first
month
hsct
earli
studi
show
donor
lymphocyt
infus
dli
given
tcell
reconstitut
stem
cell
donor
effect
treat
viral
infect
hsct
recipi
associ
high
risk
gvhd
sinc
earli
investig
began
develop
virusspecif
cytotox
lymphocyt
vctl
adopt
immunotherapi
specif
target
earli
immun
reconstitut
hsct
advanc
vctl
therapi
benefit
advanc
understand
immun
respons
conserv
tcell
epitop
variou
pathogen
technolog
advanc
ex
vivo
expans
cell
advanc
prepar
antigenpres
cell
assay
evalu
vctl
activ
mhc
restrict
vctl
chapter
review
follow
area
cell
expand
target
multipl
pathogen
vctl
product
longer
requir
viral
infect
viral
vector
transduct
antigenpres
cell
apc
sourc
lymphocyt
longer
restrict
donor
immun
pathogen
naiv
cell
redirect
chimer
antigen
receptor
cell
cart
target
pathogeninfect
cell
bispecif
antibodi
biab
arm
cell
bat
mediat
vctl
activ
pathogenspecif
tcell
product
manufactur
third
parti
bank
offtheshelf
use
posthsct
summar
methodolog
approach
clinic
trial
use
vctl
promis
preclin
studi
earli
clinic
trial
antipathogen
ctl
promis
advanc
provid
rational
impetu
futur
vctl
adopt
immunotherapi
product
vctl
guid
principl
decreas
risk
gvhd
allogen
hsct
recipi
strategi
exclud
alloreact
cell
select
virusspecif
cell
four
major
approach
use
stimul
viral
antigen
ex
vivo
cultur
donor
cell
peripher
blood
mononuclear
cell
pbmc
direct
select
donor
cell
genet
modif
cell
confer
specif
recognit
pathogen
pathogeninfect
cell
arm
ex
vivo
expand
cell
bispecif
antibodi
target
viral
antigen
fig
numer
ex
vivo
cultur
approach
use
produc
cytomegaloviru
cmv
specif
ctl
epsteinbarr
viru
ebv
specif
ctl
cmv
viralor
peptidespecif
stimul
vitro
expand
singl
multipl
pathogenspecif
vctl
advantag
cultur
cell
select
gener
expans
polyclon
vctl
clinic
use
quantiti
vctl
small
amount
blood
howev
major
disadvantag
strategi
daunt
task
cultur
process
stimul
expand
vctl
month
hlahistocompat
requir
find
close
match
donor
longerterm
cultur
vctl
may
lose
capac
selfrenew
persist
vivo
particularli
prolong
ex
vivo
cultur
note
clinic
trial
infus
ex
vivo
expand
vctl
posthsct
show
prolong
persist
ex
vivo
expans
use
pathogenspecif
stimuli
decreas
alloreact
may
due
select
virusspecif
clone
deselect
alloreact
clone
one
studi
show
residu
alloreact
seen
vctl
clinic
insignific
initi
trial
vctl
therapi
requir
cmv
lysat
apc
cmvinfect
fibroblast
ebvlymphoblastoid
cell
line
stimul
expans
donorderiv
memori
cell
discoveri
domin
highli
conserv
antigen
adenoviru
hexon
penton
led
replac
live
viral
stimul
either
peptid
pool
span
viral
protein
dna
plasmidtransduc
antigenpres
cell
newer
approach
rapidli
expand
manipul
apc
enabl
use
less
restrict
popul
donor
target
increas
number
pathogen
singl
cultur
recent
rapid
vctl
protocol
addit
lead
product
cell
th
phenotyp
wherea
tend
favor
vitro
natur
killer
nk
cell
expans
ideal
popul
adopt
transfer
may
ex
vivo
expand
central
memori
cell
phenotyp
cell
superior
abil
persist
vivo
adopt
transfer
select
via
cell
captur
sort
direct
select
reli
cell
sort
immun
donor
pbmc
usual
puls
antigen
interest
drive
expans
virusspecif
tcell
clone
approach
would
viabl
obtain
immun
ctl
pathogenna
donor
multim
select
achiev
bind
hlapeptid
complex
tcell
receptor
tcr
known
antigen
specif
follow
purif
bound
cell
eg
magnet
column
separ
altern
antivir
cell
express
isol
use
gamma
captur
assay
direct
select
method
advantag
rapid
manufactur
time
unfortun
approach
requir
apheresi
donor
order
collect
suffici
cell
sort
process
clinic
applic
preexist
detect
pathogenspecif
cell
blood
multim
select
major
histocompat
mhc
restrict
select
cell
limit
specif
could
possibl
allow
pathogen
evas
impair
persist
vctl
vivo
earlier
studi
suggest
persist
bind
multim
tcr
may
impair
tcell
function
recent
revers
streptam
technolog
direct
select
may
overcom
problem
impair
function
posit
select
captur
polyclon
antigenspecif
cell
select
wider
rang
antigenspecif
cell
combin
direct
select
cultur
expans
method
cytokin
cocktail
optim
select
central
memori
cell
vctl
product
improv
yield
target
cellular
phenotyp
tcr
car
gene
modif
cell
modifi
redirect
specif
retrovir
lentivir
vector
introduc
transgen
highaffin
tcr
chimer
antigen
receptor
car
consist
singlechain
variabl
fragment
scfv
highaffin
tcr
gene
clone
transduc
polyclon
cell
gener
larg
popul
blood
obtain
donor
autolog
allogen
umbil
cord
blood
drawn
apheresi
perform
obtain
larger
quantiti
blood
pbmc
process
via
cell
select
panel
use
multim
pathogenderiv
peptid
associ
typei
hla
molecul
column
select
vitro
stimul
cell
antigen
follow
bind
cell
antibodyco
immunomagnet
bead
b
cell
expans
stimul
pbmc
apc
produc
antigen
peptid
pool
viral
transduct
nucleofect
c
genet
modif
involv
transfer
highaffin
pathogenspecif
tcr
car
redirect
specif
cell
polyclon
expans
cell
day
arm
biab
direct
pathogen
interest
one
hand
tcr
hand
qualiti
control
releas
test
infus
patient
tcr
pathogenspecif
ctl
similar
strategi
use
produc
tumorspecif
cell
tcr
gene
transfer
contrast
car
extracellular
region
consist
scfv
bind
antigen
intracellular
signal
complex
compos
tcr
zeta
chain
firstgener
car
tcr
zeta
chain
secondgener
car
tcr
zeta
thirdgener
car
highaffin
tcrtransduc
ctl
use
target
cmvinfect
cell
hpvinfect
cell
hepat
binfect
cell
hepat
cinfect
cell
tuberculosisinfect
cell
sarsinfect
cell
chlamydiainfect
cell
hivinfect
cell
car
cell
use
target
hivinfect
cell
recognit
fungi
ex
vivo
ctl
expans
common
method
produc
clinic
ctl
clinic
trial
cmv
primari
focu
first
viru
target
therapi
trial
remain
primari
focu
subsequ
studi
tabl
first
clinic
report
cmvspecif
ctl
isol
via
tetram
select
gener
complet
partial
clinic
respons
nine
patient
limit
data
longterm
persist
infus
cmvspecif
ctl
column
select
gamma
captur
miltenyi
produc
cmvctl
associ
partial
complet
respons
patient
given
one
dose
cmvctl
select
stimul
recombin
overlap
peptid
pool
cover
protein
use
produc
cmvctl
infus
cmvctl
administ
prophylact
stem
cell
transplant
success
protect
seven
patient
develop
viral
reactiv
diseas
vivo
expans
cmvctl
detect
patient
cmvctl
hsct
donor
use
revers
streptam
mhcrestrict
peptid
use
success
treat
two
patient
cmv
reactiv
hct
strategi
use
bispecif
antibodi
biab
target
cancer
nearli
abandon
due
cytokin
storm
reaction
howev
last
year
seen
resurrect
interest
particularli
target
cell
variou
cancer
antigen
studi
use
retarget
cell
report
breast
prostat
cancer
use
x
biab
atc
egfr
colorect
pancreat
lung
cancer
use
x
antiegfr
biab
atc
nonhodgkin
lymphoma
use
x
biab
atc
sinc
chemic
molecularli
engin
construct
could
use
target
tcr
one
hand
tumorassoci
antigen
taa
hand
reason
cmv
could
target
chemic
heteroconjug
antitcr
polyclon
donorderiv
anticmv
igg
design
cmvbi
kill
cmvinfect
fibroblast
strategi
shown
fig
monoclon
antibodyactiv
cell
atc
expand
lowdos
effector
cell
atc
alon
kill
cmvinfect
target
arm
dose
cmvbi
rang
low
atc
atc
exhibit
high
level
specif
anticmv
cytotox
target
infect
cmv
multipl
cmv
infect
moi
rang
polyclon
natur
cytogam
may
provid
multipl
antibodi
clone
direct
multipl
cmv
epitop
cmvinfect
target
lead
increas
potenc
low
arm
dose
cmvbi
cytotox
evid
effectortotarget
ratio
e
compar
unarm
atc
alon
moi
mean
specif
anticmvspecif
cytotox
e
respect
wherea
unarm
atc
e
ts
kill
unarm
atc
cmvbi
alon
exhibit
signific
kill
uninfect
cmvinfect
fibroblast
furthermor
cultur
cmvbiarm
atc
cmvinfect
target
induc
cytokin
chemokin
releas
cmvbiarm
atc
simpl
target
strategi
bypass
mhcrestrict
cytotox
treat
viral
diseas
organ
transplant
hsct
recipi
shown
cmvbi
atc
react
alloantigen
vitro
mix
lymphocyt
cultur
frozen
reinfus
differ
time
point
offtheshelf
drug
although
promis
clear
data
whether
target
cmv
diseas
agent
use
approach
clinic
effect
ebvctl
use
prevent
treatment
posthsct
lymphoprolif
diseas
ptld
well
ebv
lymphoma
irradi
ebvlymphoblastoid
cell
ebvlcl
use
gener
ebvspecif
ctl
vitro
prophylaxi
treatment
ebvptld
patient
remark
first
patient
receiv
genemark
ctl
followup
studi
show
genemark
cell
persist
month
hsct
tabl
pentam
select
procedur
use
produc
ebvctl
specif
pentam
use
produc
ebvctl
haploident
mother
patient
ebvptld
receiv
cord
blood
transplant
complet
clinic
respons
obtain
follow
two
infus
ebvctl
three
six
patient
earli
ebvinduc
ptld
treat
ebvctl
produc
select
achiev
complet
respons
wherea
three
patient
advanc
multiorgan
diseas
respond
latest
strategi
target
ebv
multivir
ctl
product
thirdpartyderiv
ebvctl
studi
target
adenoviru
adv
use
multivir
ctl
exclus
target
adv
select
technolog
advctl
produc
select
use
treatment
nine
patient
drugrefractori
adv
infect
vivo
ctl
expans
five
six
patient
four
patient
clear
diseas
studi
use
cell
select
clinic
benefit
observ
spite
low
dose
vctl
infus
cellskg
studi
recent
antivir
ctl
therapi
trial
target
multipl
virus
cmv
ebv
adv
primari
target
cmv
ebv
adv
three
lead
caus
viralassoci
mortal
allogen
hsct
clinicalgrad
adv
vector
contain
immunodomin
cmv
antigen
provid
uniqu
opportun
transduc
donorderiv
dendrit
cell
ebvlcl
serv
apc
ctl
cultur
trivir
cmv
ebv
advspecif
ctl
test
doseescal
trial
involv
patient
advers
effect
dose
rang
cellsm
patient
effect
protect
cmv
ebv
adv
interestingli
although
ebvand
cmvspecif
ctl
detect
elispot
advctl
detect
except
infect
followup
trial
use
ebvlcl
produc
ebvand
advctl
patient
receiv
prophylaxi
treatment
ebv
adv
infect
hsct
although
ctl
provid
protect
vivo
advctl
could
detect
except
set
adv
infect
data
suggest
level
specif
vctl
limit
detect
elispot
provid
protect
infect
induc
clonal
expans
similarli
transduc
dendrit
cell
dc
use
produc
cmvand
advctl
clinic
effect
patient
allogen
hsct
case
cmv
reactiv
set
lowdos
prednison
approach
appli
patient
allogen
hsct
trivir
cmv
ebv
advspecif
ctl
use
two
method
produc
puls
donor
dc
restrict
cmv
peptid
nlvpmvatv
produc
use
donor
dc
patient
cmv
reactiv
ctl
infus
patient
requir
antivir
drug
therapi
steroid
treatment
acut
gvhd
advanc
process
protocol
valid
peptid
pool
includ
immunodomin
viral
antigen
replac
viral
transduct
apc
therebi
remov
safeti
regulatori
barrier
associ
use
viral
vector
use
gasperm
rapidexpans
grex
bioreactor
simplifi
ctl
cultur
advanc
technolog
led
develop
rapid
manufactur
protocol
expand
virusspecif
tcell
product
vst
yield
clinic
relev
number
vst
day
vst
product
target
multipl
viral
antigen
shown
provid
effect
antivir
protect
cnv
ebv
ad
ten
patient
hsct
rapid
manufactur
protocol
subsequ
adapt
produc
five
virusspecif
ctl
target
ebv
cmv
adv
bk
viru
infect
singl
tcell
product
patient
follow
allogen
hsct
fourteen
vst
product
manufactur
hsct
donor
recogn
viral
compon
recogn
elispot
unexpectedli
donor
cmv
seroneg
vst
produc
predict
lack
cmv
specif
vst
use
treat
patient
hsct
patient
treat
prophylact
remain
free
viral
infect
patient
viral
reactiv
receiv
vst
experienc
partial
complet
respons
cmv
ebv
adv
infect
although
intens
interest
use
ctl
therapi
hiv
limit
success
date
attempt
expand
reinfus
autolog
hivspecif
ctl
result
transient
improv
viral
load
larger
number
clinic
trial
focus
genet
modifi
ctl
target
hiv
use
transduct
modifi
tcr
car
trial
establish
safeti
exhibit
limit
antivir
efficaci
major
challeng
approach
outgrowth
escap
mutant
express
alter
target
epitop
infect
cell
longer
target
effector
cell
success
approach
insert
gene
would
provid
hiv
resist
approach
clinic
test
antisens
gene
complementari
hiv
env
transduc
cell
patient
use
lentivir
vector
ctl
persist
week
home
gutassoci
lymphoid
tissu
welltoler
clinic
toxic
infus
ctl
two
eight
patient
underw
antivir
treatment
interrupt
keep
viral
load
u
ndetect
week
mutat
introduc
cell
use
zincfing
nucleas
cell
subsequ
infus
patient
engin
cell
detect
peripher
blood
month
post
infus
six
patient
underw
antivir
treatment
interrupt
absolut
number
gene
modifi
cell
decreas
lower
rate
nonmodifi
cell
recent
studi
show
dual
gene
edit
via
zincfing
nucleas
success
tcell
line
preclin
studi
show
cell
highli
resist
hiv
infect
clear
whether
approach
could
prevent
primari
infect
clinic
impact
hiv
cure
strategi
studi
target
virus
adopt
immunotherapi
john
cunningham
viru
jcv
ubiquit
polyoma
viru
caus
progress
multifoc
leukoencephalopathi
pml
occur
immunocompromis
individu
acquir
immunodefici
syndrom
aid
recipi
hsct
solid
organ
transplant
primari
immunodefici
disord
donorderiv
jcvspecif
ctl
use
patient
pml
prolong
steroid
treatment
gvhd
follow
hsct
cell
manufactur
use
peptid
pool
includ
jc
antigen
lt
infus
twice
lead
clearanc
jvdna
cerebrospin
fluid
improv
neurolog
statu
human
papillomaviru
hpv
diseas
late
complic
hsct
peptid
pool
span
hpv
protein
use
gener
hpvspecif
ctl
patient
oropharyng
cervic
cancer
aris
infect
ctl
exhibit
specif
activ
direct
hpv
antitumor
activ
cervic
cancer
cell
line
caski
advers
event
infus
patient
protocol
group
baylor
colleg
medicin
report
side
effect
limit
mild
advers
event
observ
within
h
infus
nausea
vomit
common
nonseri
advers
event
fever
chill
nausea
occur
within
h
signific
gvhd
attribut
ctl
infus
signific
complic
rare
report
system
inflammatori
respons
patient
bulki
ebv
lymphoma
follow
ebvctl
therapi
seven
case
acut
gvhd
occur
patient
greater
degre
hla
mismatch
control
infus
ebvctl
case
gvhd
attribut
reduc
corticosteroid
dose
prior
cmvctl
infus
year
select
cultur
antipathogen
ctl
depend
presenc
pathogenspecif
memori
cell
blood
donor
therefor
approach
could
help
allograft
recipi
pathogenna
hematopoiet
cell
product
hsct
one
strategi
address
problem
provid
offtheshelf
pathogenspecif
ctl
deriv
thirdparti
donor
strategi
first
valid
phase
trial
involv
patient
receiv
partial
match
ebvctl
ptld
develop
solid
organ
transplant
confirm
cohort
patient
phase
ii
trial
latter
trial
show
respons
rate
week
month
outcom
correl
degre
hla
match
ctl
donor
recipi
hsct
patient
two
patient
refractori
ebvptld
cord
blood
transplant
cbt
thirdparti
ebvspecif
ctl
bank
ctl
line
character
activ
ebv
cmv
adv
use
match
patient
refractori
viral
infect
strategi
result
partial
complet
antivir
respons
cmv
adv
ebv
respect
mark
improv
standard
therapi
respons
rate
eight
patient
match
line
could
identifi
despit
partial
hla
match
one
four
loci
two
patient
develop
grade
gvhd
clone
respons
gvhd
select
expans
cultur
may
exist
low
precursor
frequenc
cultur
expand
enough
caus
clinic
signific
gvhd
lower
rate
respons
ebv
rel
cmv
adv
may
reflect
select
expans
cell
immunodomin
epitop
latter
two
virus
therebi
complic
select
ideal
thirdparti
pathogenspecif
line
fulfil
requir
antivir
activ
mhcrestrict
multipl
pathogen
method
produc
thirdpartyvirusspecif
ctl
includ
pentam
select
ad
cmv
ebv
select
advctl
studi
report
transduc
ctl
virusspecif
tcr
trial
transgen
ctl
use
retrovir
vector
express
cmvspecif
tcr
ongo
unit
kingdom
morri
e
et
al
mrc
altern
kumaresan
et
al
transduc
cell
receptor
dectin
sinc
carbohydr
found
cell
wall
fungi
investig
use
natur
receptor
recognit
receptor
coupl
key
costimulatori
molecul
transgen
initi
signal
kill
cell
group
show
antifung
cart
could
mediat
damag
hypha
vitro
vivo
novel
approach
would
allow
creation
specif
ctl
pathogenna
donor
howev
subject
regulatori
challeng
gene
transfer
technolog
furthermor
use
singl
antifung
tcr
allow
antigen
escap
major
advanc
adopt
viral
ctl
therapi
develop
virusspecif
ctl
virusna
donor
ctl
could
produc
fraction
cord
blood
use
donorderiv
dc
ebvlymphoblastoid
cell
line
lcl
apc
transduct
sourc
cmv
adv
antigen
result
viral
ctl
exhibit
specif
anticmv
ebv
adv
elispot
respons
well
specif
cr
cytotox
alloreact
epitop
map
show
immunodomin
epitop
recogn
cord
bloodderiv
ctl
differ
immunodomin
epitop
recogn
cmv
ebv
seroposit
adult
donor
epitop
nlvpmvatv
notabl
absent
cord
bloodderiv
line
ctl
deriv
cord
blood
success
infus
cbt
recipi
ongo
actcat
trial
safeti
toxic
mtd
one
intraven
iv
inject
donor
ctl
specif
cmv
adenoviru
recent
multivir
ctl
produc
cmvnaiv
adult
donor
use
columnselect
naiv
cell
stimul
donor
dc
puls
cmv
peptid
pool
preclin
studi
suggest
multivir
ctl
exhibit
similar
anticmv
activ
dc
puls
cmv
peptid
pool
ebvptld
signific
longterm
risk
solid
organ
transplant
recipi
rituximab
effect
treatment
often
requir
reduct
immunosuppress
lead
graft
reject
autolog
ebvctl
use
set
sever
prophylact
infus
autolog
ebvctl
reduc
ebv
viral
load
without
advers
reaction
despit
ongo
treatment
calcineurin
inhibitor
heart
transplant
recipi
develop
hodgkin
lymphomatyp
ptld
year
transplant
remiss
treat
autolog
ebvctl
combin
chemotherapi
without
alter
immunosuppress
observ
support
prior
observ
calcineurin
inhibitor
block
prolifer
impair
ctl
activ
fungal
infect
major
caus
morbid
mortal
allogen
hsct
recipi
gvhd
major
risk
factor
candid
infect
rang
mucocutan
colon
skin
mouth
lifethreaten
system
infect
aspergillu
speci
ubiquit
mold
caus
invas
pulmonari
infect
well
widespread
infect
includ
central
nervou
system
dissemin
highli
immunocompromis
patient
patient
inherit
immunodefici
eg
chronic
granulomat
diseas
patient
prolong
neutropenia
repeat
round
chemotherapi
eg
acut
leukemia
receiv
immunosuppress
lung
transplant
allogen
hsct
highest
risk
mycos
import
tcell
immun
defens
invas
aspergillosi
filament
fungi
clear
sinc
patient
invas
fungal
diseas
usual
sever
defici
multipl
compon
immun
system
patient
advanc
aid
invas
aspergillosi
uncommon
complic
gener
occur
form
immun
impair
eg
neutropenia
use
corticosteroid
present
despit
unknown
may
clinic
use
target
fungal
infect
fungusspecif
cell
hsct
adapt
immun
respons
invas
aspergillosi
believ
orchestr
cell
tabl
summar
preclin
studi
develop
fungalspecif
ctl
candida
aspergillu
rhizopu
member
mucoral
group
speci
aspergillusspecif
ctl
produc
stimul
pbmc
antigen
aspergillu
extract
select
secret
cultur
ctl
predominantli
memori
cell
secret
respons
aspergillu
penicillium
fungalspecif
ctl
enhanc
hyphal
damag
neutrophil
apc
select
stimul
candida
albican
aspergillu
fumigatu
rhizopu
oryza
extract
use
produc
multifungalspecif
ctl
line
also
nearli
hladr
exhibit
activ
marker
enhanc
oxid
activ
neutrophil
coincub
antigen
apc
sever
studi
target
candida
aspergillu
antigen
produc
multipathogenspecif
cell
secret
prolifer
kill
cmv
ebv
adv
candida
aspergillu
donor
pbmc
incub
peptid
librari
advhexon
candida
peptid
aspergillu
howev
remain
unclear
signific
antifung
immun
expand
memoryeffector
cell
follow
stimul
rhizopu
extract
use
gener
memoryeffector
cell
mucormycosi
product
exhibit
specif
origin
rhizopu
oryza
extract
well
mucoral
speci
candidaspecif
cell
gener
cellular
extract
candida
albican
releas
cytokin
caus
hyphal
damag
increas
neutrophil
activ
hypha
ctl
produc
stimul
inactiv
conidia
spore
aspergillu
fumigatu
result
clonal
ctl
antiaspergillu
activ
elispot
donor
tcell
clone
specif
aspergillu
antigen
infus
patient
follow
haploident
hsct
patient
develop
invas
aspergillosi
patient
receiv
antiaspergillu
ctl
patient
nine
treat
patient
clear
infect
wherea
untreat
patient
clear
infect
aspergillusspecif
ctl
detect
high
frequenc
patient
receiv
immunotherapi
bare
detect
untreat
patient
despit
notabl
advanc
antifung
ctl
better
understand
immunodomin
tcell
target
select
variou
fungal
speci
need
standard
clinicalgrad
cgmp
fungal
antigen
sourc
need
provid
consist
trial
although
major
advanc
produc
pathogenspecif
ctl
import
question
remain
regard
method
affect
potenc
efficaci
tcell
product
unclear
whether
manufactur
ctl
includ
pathogen
singl
cultur
affect
potenc
specif
ctl
cultur
although
proport
virusspecif
ctl
viru
decreas
number
antigen
increas
effect
seem
impact
clinic
trial
ctl
specif
virus
cmv
ebv
adv
bk
rsv
influenza
produc
use
peptid
pool
antigen
exhibit
specif
activ
target
virus
question
remain
whether
ad
addit
viral
target
skew
specif
cytotox
alter
potenc
target
induc
alloreact
cell
compromis
vivo
respons
major
challeng
achiev
consist
optim
cultur
condit
gener
effect
ctl
product
although
multipl
round
stimul
antigen
select
expand
specif
antivir
clone
prolong
cultur
may
lead
tcell
exhaust
group
decreas
product
time
use
newer
bioreactor
identif
correct
subset
cell
clinic
use
howev
select
requir
welldesign
random
phase
ii
trial
use
specif
ctl
product
made
group
common
standard
oper
procedur
sop
homogen
group
hsct
patient
assay
measur
elispot
cytotox
need
standard
time
studi
need
recent
new
popul
healthi
donor
jolink
transgen
tcrtransduc
cell
tuberculosi
murin
cell
feng
mhcstreptamerenrich
antigenspecif
cell
listeria
murin
cell
stemberg
proof
principl
target
ovaexpress
parasit
murin
cell
polley
transgen
trctransduc
cell
chlamydia
murin
cell
roan
stem
cell
memori
cell
put
identifi
possess
characterist
ideal
use
adopt
immunotherapi
unfortun
random
phase
ii
trial
date
support
continu
develop
commerci
clinic
effect
ctl
presenc
immunosuppress
remain
barrier
optim
immunotherapi
allogen
hsct
solid
organ
transplant
sinc
agent
also
suppress
ctl
function
nearli
protocol
requir
recipi
receiv
less
mgkgday
prednison
wait
least
day
antitcel
serotherapi
elig
receiv
ctl
therapi
virtual
calcineurin
inhibitor
cyclosporin
tacrolimu
sirolimu
therapeut
dose
impair
ctl
activ
ebvspecif
ctl
made
resist
tacrolimu
knockdown
via
retrovir
transduc
specif
sirna
exhibit
antiebv
lymphoma
activ
presenc
tacrolimu
similarli
ebvspecif
ctl
made
resist
cyclosporin
tacrolimu
mutat
calcineurin
mutat
alter
phenotyp
antivir
activ
ctl
mutat
cell
growth
advantag
calcineurin
inhibitor
although
appli
clinic
great
potenti
treat
hsct
solid
organ
transplant
recipi
one
preclin
report
cell
use
target
bacteri
parasit
infect
clinic
trial
evalu
tcell
immunotherapi
bacteri
parasit
infect
despit
numer
studi
evalu
vitro
tcell
respons
consensu
role
cell
defens
aspergillosi
infus
antipathogen
ctl
sever
hundr
patient
past
sever
decad
establish
safe
highli
effect
therapi
follow
allogen
hct
identifi
preserv
viral
tcell
epitop
probe
antigen
limit
ctl
monocultur
test
clinic
efficaci
immunosuppressiveresist
ctl
improv
condit
rapid
specif
expans
broaden
use
treatment
strategi
advanc
protocol
method
manufactur
achiev
accept
clinic
standard
support
commerci
ctl
therapi
may
becom
integr
compon
care
offer
allogen
hsct
immunodefici
patient
